June 2024 in “Drug and therapeutics bulletin” Finasteride can cause depression, suicidal thoughts, and lasting psychiatric and sexual issues.
January 2026 in “British Journal of Clinical Pharmacology” In this study, reports from individuals using Serenoa repens indicated a possible post-Serenoa syndrome characterized by persistent sexual and neuropsychiatric symptoms, with causality assessed as 'probable' in 54% of cases, highlighting an underrecognized safety concern that warrants further investigation.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.
July 2023 in “Health science reports” In this study, researchers examined the prevalence of comorbid conditions among 402 alopecia areata patients, finding that hypothyroidism was notably more frequent in women, while hyperlipidemia was more common in men, with overall thyroid function testing suggested for these patients.
January 2021 in “Open MIND” This scoping review aims to explore the impact of hormone therapy on the laboratory profiles of transgender people, identify evidence, and highlight literature gaps, particularly in developing countries.